Golimumab BS F
Golimumab biosimilar developed by Fuji Pharma. Reference product Simponi (Simponi Aria intravenous in the United States).
About Golimumab BS F
Golimumab BS F is Fuji Pharma's golimumab, approved in Japan in September 2025 for rheumatoid arthritis, the first golimumab biosimilar in Japan and, at the time, the first anywhere outside India. Fuji Pharma has not named the developer.
Status by market
United States
Not listed by FDA.
European Union
Not listed by EMA.
United Kingdom
Not listed by MHRA.
Japan · Golimumab BS F
Pharmaceuticals and Medical Devices Agency and MHLWApprovedCanada
Not listed by HC.
India
Not listed by CDSCO.
United Arab Emirates
Not listed by EDE.
Same developer, other molecules
Other biosimilars in the Atlas developed by Fuji Pharma: Aflibercept BS NIT, Denosumab BS F, Filgrastim BS F / Mochida, Ustekinumab BS F.
Chronology
- PMDASep 2025Approved by MHLW
Sources
S020PMDA, list of approved biosimilar products in Japan (as of July 2026) Primary (regulator)
Planning golimumab biosimilar development?
EvySaif can help assess your regulatory pathway, clinical evidence requirements and market-entry strategy across India, UAE and other target markets.
Talk to a biosimilar regulatory consultant